Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate‐Lowering Therapy in Ontario, Canada
Authors' conclusion
SUA testing is suboptimal among older adults with gout initiating ULT but is improving over time. ULT prescriber, patient, and prescription characteristics were correlated with SUA testing.
Study context
- Population
- Patients aged ≥66 years with gout newly dispensed urate-lowering therapy (ULT) between 2010 and 2019, Ontario, Canada
- Participants
- 44,438 patients
- Outcome
- SUA testing after ULT initiation; factors associated with SUA monitoring
- Follow-up
- 6 months
Methodological detailspopulation-based, multilevel logistic regression clustered by ULT prescriber
- Population-based
- Multilevel logistic regression clustered by ULT prescriber
Main finding
As reported in the abstract
Factors associated with SUA monitoring within 6 months (vs rheumatologists for prescriber specialty)
Odds ratio (95% CI)
Family physiciansvs Rheumatologists
0.26(0.23–0.29)
Internistsvs Rheumatologists
0.34(0.29–0.39)
Nephrologistsvs Rheumatologists
0.37(0.30–0.45)
Other specialtiesvs Rheumatologists
0.25(0.21–0.29)
Male physicians
0.87(0.83–0.91)
Rural residence
0.81(0.77–0.86)
Lower socioeconomic status
0.91(0.85–0.97)
Coprescription of colchicine/oral corticosteroids
1.31(1.23–1.40)
- Serum urate (SUA) testing at 6 months in 2010
- 56.4%
- SUA testing in 2019 (rose over time)
- 71.3%
- Trend over time
- P < 0.0001
Observational data: associations, not effects.
Original publication
Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate‐Lowering Therapy in Ontario, Canada. Arthritis Care Res (Hoboken). Published 26 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →